Quoin Pharmaceuticals Ltd宣布已完成日本子公司的设立,此举旨在为其候选药物QRX003的商业化进程做好前期准备。公司计划在2026年下半年启动QRX003的三期临床试验,并有望在2027年提交新药上市申请。
Quoin Pharmaceuticals Ltd宣布已完成日本子公司的设立,此举旨在为其候选药物QRX003的商业化进程做好前期准备。公司计划在2026年下半年启动QRX003的三期临床试验,并有望在2027年提交新药上市申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.